Literature DB >> 31638228

ACSS2/AMPK/PCNA pathway‑driven proliferation and chemoresistance of esophageal squamous carcinoma cells under nutrient stress.

Lei Mi1, Yuepeng Zhou1, Dan Wu1, Qing Tao1, Xuefeng Wang2, Haitao Zhu3, Xingyu Gao1, Jingzhi Wang1, Rui Ling1, Jing Deng4, Chaoming Mao1, Deyu Chen1.   

Abstract

Although platinum‑based chemotherapy is the first‑line choice for locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients, accelerated recurrence and chemoresistance remain inevitable. New evidence suggests that metabolism reprogramming under stress involves independent processes that are executed with a variety of proteins. This study investigated the functions of nutrient stress (NS)‑mediated acetyl‑CoA synthetase short‑chain family member 2 (ACSS2) in cell proliferation and cisplatin‑resistance and examined its combined effects with proliferating cell nuclear antigen (PCNA), a key regulator of DNA replication and repair. Here, it was demonstrated that under NS, when the AMP‑activated protein kinase (AMPK) pathway was activated, ESCC cells maintained proliferation and chemoresistance was distinctly upregulated as determined by CCK‑8 assay. As determined using immunoblotting and RT‑qPCR, compared with normal esophageal epithelial cells (Het‑1A), ESCC cells were less sensitive to NS and showed increased intracellular levels of ACSS2. Moreover, it was shown that ACSS2 inhibition by siRNA not only greatly interfered with proliferation under NS but also participated in DNA repair after cisplatin treatment via PCNA suppression, and the acceleration of cell death was dependent on the activation of the AMPK pathway as revealed by the Annexin V/PI and TUNEL assay results. Our study identified crosstalk between nutrient supply and chemoresistance that could be exploited therapeutically to target AMPK signaling, and the results suggest ACSS2 as a potential biomarker for identifying higher‑risk patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31638228     DOI: 10.3892/mmr.2019.10735

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism.

Authors:  Mengfang Liu; Na Liu; Jinlei Wang; Shengqiao Fu; Xu Wang; Deyu Chen
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

2.  Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.

Authors:  Alexander Mathilakathu; Sabrina Borchert; Michael Wessolly; Elena Mairinger; Hendrik Beckert; Julia Steinborn; Thomas Hager; Daniel C Christoph; Jens Kollmeier; Jeremias Wohlschlaeger; Thomas Mairinger; Kurt Werner Schmid; Robert F H Walter; Luka Brcic; Fabian D Mairinger
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 3.  Acetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development.

Authors:  Rui Ling; Gong Chen; Xiang Tang; Na Liu; Yuepeng Zhou; Deyu Chen
Journal:  Discov Oncol       Date:  2022-07-07

4.  SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway.

Authors:  Jun Ding; Daming Qin; Yong Zhang; Qinghe Li; Yi Li; Jinmao Li
Journal:  Mol Med Rep       Date:  2020-01-03       Impact factor: 2.952

Review 5.  Role of circular RNAs in gastrointestinal tumors and drug resistance.

Authors:  Shi-Jun Xi; Wen-Qi Cai; Qin-Qi Wang; Xiao-Chun Peng
Journal:  World J Clin Cases       Date:  2021-12-06       Impact factor: 1.337

Review 6.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.